ULTRAGENYX PHARMACEUTICAL INC. Earnings Per Share, Basic and Diluted
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Earnings Per Share, Basic and Diluted of -$2.26 per share for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-07-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-07-29
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for the quarter ending 2022-06-30 was -$2.26.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$2.19.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$1.08.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.81.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for fiscal 2021 was -$6.70.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for fiscal 2020 was -$3.07.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for fiscal 2019 was -$7.12.
- ULTRAGENYX PHARMACEUTICAL INC. earnings per share, basic and diluted for fiscal 2018 was -$3.97.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-06-30 | -$2.26 10-Q · filed 2022-07-29 | -$4.45 10-Q · filed 2022-07-29 | ||
| 2022-03-31 | -$2.19 10-Q · filed 2022-05-06 | |||
| 2021-12-31 | -$6.70 10-K · filed 2022-02-15 | |||
| 2021-09-30 | -$1.08 10-Q · filed 2021-11-03 | -$4.91 10-Q · filed 2021-11-03 | ||
| 2021-06-30 | -$1.81 10-Q · filed 2022-07-29 | -$3.84 10-Q · filed 2022-07-29 | ||
| 2021-03-31 | -$2.03 10-Q · filed 2022-05-06 | |||
| 2020-12-31 | -$3.07 10-K · filed 2022-02-15 | |||
| 2020-09-30 | -$1.13 10-Q · filed 2021-11-03 | -$2.73 10-Q · filed 2021-11-03 | ||
| 2020-03-31 | -$2.05 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | -$1.62 10-K · filed 2021-02-12 | -$7.12 10-K · filed 2022-02-15 | ||
| 2019-09-30 | -$1.96 10-K · filed 2021-02-12 | -$5.50 10-Q · filed 2020-10-27 | ||
| 2019-06-30 | -$1.72 10-K · filed 2021-02-12 | -$3.54 10-Q · filed 2019-08-02 | ||
| 2019-03-31 | -$1.82 10-K · filed 2021-02-12 | |||
| 2018-12-31 | -$3.97 10-K · filed 2021-02-12 | |||
| 2018-09-30 | -$1.74 10-Q · filed 2019-11-06 | -$2.22 10-Q · filed 2019-11-06 | ||
| 2018-06-30 | -$1.06 10-Q · filed 2019-08-02 | -$0.46 10-Q · filed 2019-08-02 | ||
| 2017-12-31 | -$1.89 10-K · filed 2019-02-20 | -$7.12 10-K · filed 2020-02-14 | ||
| 2017-09-30 | -$1.87 10-K · filed 2019-02-20 | -$5.22 10-Q · filed 2018-11-06 | ||
| 2017-06-30 | -$1.72 10-K · filed 2019-02-20 | -$3.35 10-Q · filed 2018-08-03 | ||
| 2017-03-31 | -$1.63 10-K · filed 2019-02-20 | |||
| 2016-12-31 | -$1.75 10-K · filed 2018-02-21 | -$3.39 derived: net income ÷ weighted average shares · filed 2019-02-20 | -$4.85 derived: net income ÷ weighted average shares · filed 2019-02-20 | -$6.21 10-K · filed 2019-02-20 |
| 2016-09-30 | -$1.64 10-K · filed 2018-02-21 | -$3.10 derived: net income ÷ weighted average shares · filed 2017-11-03 | -$4.46 10-Q · filed 2017-11-03 | -$5.88 derived: net income ÷ weighted average shares · filed 2018-02-21 |
| 2016-06-30 | -$1.46 10-K · filed 2018-02-21 | -$2.81 10-Q · filed 2017-07-28 | -$4.23 derived: net income ÷ weighted average shares · filed 2018-02-21 | -$5.26 derived: net income ÷ weighted average shares · filed 2018-02-21 |
| 2016-03-31 | -$1.35 10-K · filed 2018-02-21 | -$2.77 derived: net income ÷ weighted average shares · filed 2018-02-21 | -$3.80 derived: net income ÷ weighted average shares · filed 2018-02-21 | -$4.66 derived: net income ÷ weighted average shares · filed 2018-02-21 |
| 2015-12-31 | -$1.42 10-K · filed 2017-02-17 | -$2.45 derived: net income ÷ weighted average shares · filed 2018-02-21 | -$3.30 derived: net income ÷ weighted average shares · filed 2018-02-21 | -$3.96 10-K · filed 2018-02-21 |
| 2015-09-30 | -$1.03 10-K · filed 2017-02-17 | -$1.86 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.51 10-Q · filed 2016-11-08 | -$3.06 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2015-06-30 | -$0.83 10-K · filed 2017-02-17 | -$1.46 10-Q · filed 2016-08-09 | -$2.00 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.51 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2015-03-31 | -$0.63 10-K · filed 2017-02-17 | -$1.16 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$1.66 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.12 derived: net income ÷ weighted average shares · filed 2017-02-17 |
| 2014-12-31 | -$0.52 10-K · filed 2016-02-26 | -$1.03 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$1.48 derived: net income ÷ weighted average shares · filed 2017-02-17 | -$2.25 10-K · filed 2017-02-17 |
| 2014-09-30 | -$0.50 10-K · filed 2016-02-26 | -$0.95 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$1.73 10-Q · filed 2015-11-10 | -$3.06 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2014-06-30 | -$0.45 10-K · filed 2016-02-26 | -$1.25 10-Q · filed 2015-08-14 | -$2.75 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$4.29 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2014-03-31 | -$0.85 10-K · filed 2016-02-26 | -$2.93 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$5.15 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$7.52 derived: net income ÷ weighted average shares · filed 2016-02-26 |
| 2013-12-31 | -$4.98 10-K · filed 2015-03-27 | -$8.48 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$11.88 derived: net income ÷ weighted average shares · filed 2016-02-26 | -$14.87 10-K · filed 2016-02-26 |
| 2013-09-30 | -$3.48 10-K · filed 2015-03-27 | -$6.81 derived: net income ÷ weighted average shares · filed 2015-03-27 | -$9.70 10-Q · filed 2014-11-10 | |
| 2013-06-30 | -$3.32 10-K · filed 2015-03-27 | -$6.19 10-Q · filed 2014-08-11 | ||
| 2013-03-31 | -$2.84 10-K · filed 2015-03-27 | |||
| 2012-12-31 | -$14.20 10-K · filed 2015-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |